‘Santen vs. Allergan’ for the top in the xerophthalmia market
The xerophthalmia market is experiencing an upheaval. While the 2-strong formation is set among the two originals, the competition for the top is getting fiercer as ‘Diquas’ is about to take over the leading position.
‘Restasis,’ expired in patent last May, recorded significantly lowered sales d...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
